|  |  |
| --- | --- |
|  | **周 晓 燕**  **博士，教授**  **硕士生导师，赣江青年学者** |

* **教育和工作背景**

2003/09-2008/06 华中科技大学同济医学院，病理学与病理生理学，

医学博士（硕-博连读）；

2008/06-2013/12 南昌大学基础医学院，病理生理学教研室，讲师

2014/01-2019/12 南昌大学基础医学院，病理生理学教研室，副教授

2016/09-2017/09 波士顿大学医学院，生物化学与分子生物学系，访问学者；

2020/12-至今 南昌大学基础医学院，病理生理学教研室，教授

* **研究兴趣、领域：**

课题组主要致力于研究肝损伤发病机制及防治策略。近年来主持各级课题共计12项，其中国家自然科学基金4项；以通讯作者在国内外较有影响力的杂志上发表科研论文30余篇。

* **学术兼职：**

江西省生理学会常务理事，中国病理生理学会会员

* **主要成果、荣誉、奖励（代表性即可，原则上不超过10项）：**

1. Qu XQ, Chen QF, Shi QQ, Luo QQ, Zheng SY, Li YH, Bai LY, Gan S, **Zhou XY（周晓燕，Corresponding Author)**. Hepatocyte-Conditional Knockout of Phosphatidylethanolamine Binding Protein 4 Aggravated LPS/D-GalN-Induced Acute Liver Injury via the TLR4/NF-κB Pathway. Front Immunol. 2022; 13: 901566. DOI: 10.3389/fimmu.2022.901566.  IF:8.8
2. Luo QQ, Ling YY, Li YF, Qu XQ, Shi QQ, Zheng SY, Li YH, Huang YH, **Zhou XY（周晓燕，Corresponding Author)**. Phosphatidylethanolamine-Binding Protein 4 Deficiency Exacerbates Carbon Tetrachloride-Induced Liver Fibrosis by Regulating the NF-κB Signaling Pathway. Front Pharmacol. 2022; 964829. DOI:10.3389/fphar.2022.964829. IF:6.0
3. Xu F, Zhang JM, **Zhou XY（周晓燕，Corresponding Author)**, Hua Hao. Lipoxin A4 and its analog attenuate high fat diet-induced atherosclerosis via Keap1/Nrf2 pathway. Exp Cell Res 2022;412(1):113025. DOI: 10.1016/j.yexcr.2022.113025
4. Zhang JM, **Zhou XY（周晓燕，Corresponding Author)**, Hua Hao. Macrophage phenotype-switching in cancer. Eur J Pharmacol. 2022; 931:175229. DOI: 10.1016/j.ejphar.2022.175229.
5. Zhang T, Hao H, Zhou ZQ, Zeng T, Zhang JM, **Zhou XY（周晓燕，Corresponding Author)**. Lipoxin A4 inhibited the activation of Hepatic Stellate Cells-T6 cells by modulating profibrotic cytokines and NF-κB signaling pathway. Prostaglandins Other Lipid Mediat. 2020;146:106380.
6. Luo ZK,Chen QF, Qu XQ, **Zhou XY（周晓燕，Corresponding Author)**.The Roles And Signaling Pathways Of Phosphatidylethanolamine-Binding Protein 4 In Tumors.Onco Targets Ther. 2019 Sep 18;12:7685-7690.
7. Zhang T, Hao H, **Zhou XY（周晓燕，Corresponding Author).** The role of lipoxin in regulating tumor immune microenvironments. Prostaglandins Other Lipid Mediat. 2019 Oct;144:106341.
8. Chen QF, Hao H, Kuang XD, Hu QD, Huang YH, **Zhou XY（周晓燕，Corresponding Author)**. BML-111, a lipoxin receptor agonist, protects against acute injury via regulating the renin angiotensin-aldosterone system. Prostaglandins Other Lipid Mediat.  2019;140:9-1
9. Chen QF, Kuang XD, Yuan QF, Hao H, Zhang T, Huang YH, **Zhou XY（周晓燕，Corresponding Author)**. Lipoxin A4 attenuates lipopolysaccharide-induced acute lung injury via activation of the ACE2-Ang-(1-7)-Mas axis. Innate Immun. 2018;24(5):285-296.
10. Hu QD, Hu ZZ, Chen QF, Huang YH, Mao Z,  **Zhou XY（周晓燕）(Corresponding Author).** BML-111 equilibrated ACE-AngⅡ-AT1R and ACE2-Ang-(1-7)-Mas axis to protect hepatic fibrosis in rats.Prostaglandins Other Lipid Mediat. 2017;131:75-82.

**联系方式：**

电 话：18007092139

E-mail: zhouxiaoyan@ncu.edu.cn